Kornimate/medical-research-clean huggingface dataset:
cardiotoxicity assessment through comprehensive heart imaging to predict heart failure

Conditions: Cardiotoxicity; Pediatric Cancer; Heart Failure

Summary: anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. however, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. this study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. however, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. this study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies. cardiac remodeling, function, and tissue characteristics will be examined using cardiac mri in combination with other research assessments to assess the cardiotoxic effects of cancer therapy. analyses will be performed in a cohort of adolescents and young adults with a history of childhood cancer.

Eligibility criteria:
inclusion criteria: * english and spanish speaking male and female subjects, ages 13-39 years old * diagnosis of cancer at age \<22 years * previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior. exclusion criteria: * patients who have a contraindication to cardiac mri, including the presence of non-mri compatible metallic implants. * medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac mri without anesthesia. * patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus). * pregnancy (at the time of enrollment).
seum bile acid profile in type 2 diabetes and association between bile cid profile and adipokine or oxidative stress

Conditions: Type 2 Diabetes; Prediabetes; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome

Summary: "the goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (bas) in patient with type 2 diabetes mellitus (t2dm) compared with normal controls. through confirmation of different profile of bas in t2dm, investigator will suggest modulation of specific bile acids as a new possible treatment target in patients with t2dm. investigator also expect the specific bas signature will be used to screen t2dm before hyperglycemia. in addition, investigator will evaluate the association between each ba species and serum total glucagon like peptide-1 (glp-1) or fibroblast growth factor-19 (fgf-19) concentrations to determine if the specific bas profile is related with total glp-1 or fgf-19 concentration in serum. investigatr also evaluates the correlation between each ba species and metabolic profiles and oxidative stress marker to find possible roles of each ba component in glucose metabolism.


Eligibility criteria:
inclusion criteria: 1. pre-diabetes 1. defined according to the ada guideline (prediabetes definition) fpg 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l) (ifg) or 2-h pg in the 75-g ogtt 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l) (igt) or a1c 5.7-6.4% (39-46 mmol/mol) 2. type 2 diabetes 1. defined according to the ada guideline (dm definition) fpg ≥126 mg/dl (7.0 mmol/l) or 2-h pg ≥200 mg/dl (11.1 mmol/l) in the 75-g ogtt or a1c ≥6.5% (48 mmol/mol) or in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dl (11.1 mmol/l) or 2. taking any anti-diabetic medications 3. normal control 1. should not be included in other groups as above and 2. not taking any medication related to diabetes and dyslipidemia and 3. bmi \<25kg/m2 exclusion criteria: 1. subjects who refused to agree with informed consents 2. subjects with organ-transplantation 3. pregnant women 4. type 1 diabetes -

Keywords: type 2 diabetes prediabetes bile acids profile glp-1 fgf-19
combination chemotherapy plus radiation therapy in treating patients with stage iii or stage iv endometrial cancer

Conditions: Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer

Summary: phase i trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating women who have stage iii or stage iv endometrial cancer. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. combining chemotherapy with radiation therapy may kill more tumor cells.

objectives: i. determine the feasibility of doxorubicin and cisplatin followed by whole abdominal radiotherapy in patients with stage iii or iv endometrial cancer. ii. determine the acute and chronic toxic effects, in particular, severe and life-threatening gastrointestinal, hepatic, and hematologic toxic effects, of this regimen in these patients. outline: this is a multicenter study. patients receive doxorubicin iv and cisplatin iv on day 1. treatment repeats every 3 weeks for 3 courses. patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 21-53 patients will be accrued for this study within 3.5 years.

Eligibility criteria:
inclusion criteria: * histologically confirmed endometrial cancer including 1 of the following subtypes: * clear cell carcinoma * serous papillary carcinoma * endometrioid adenocarcinoma * stage iii or iv disease * positive adnexa * metastases to serosa, bowel mucosa, abdomen * positive pelvic or paraaortic nodes * positive pelvic washings or vaginal involvement within the radiation port * tumor must be surgically reduced to 2 cm or less within 8 weeks of study entry * must have had a hysterectomy and bilateral salpingo oophorectomy * no recurrent disease * no distant metastases outside of abdominopelvic area, including: * parenchymal liver metastases * lung metastases * positive inguinal lymph nodes * positive supraclavicular nodes * pleural effusion with malignant cytology * performance status - gog 0-2 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin no greater than 1.5 times upper limit of normal (uln) * sgot and alkaline phosphatase no greater than 3 times uln * creatinine no greater than uln * cardiac ejection fraction greater than 50% * no other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer * no prior chemotherapy * no prior pelvic or abdominal radiotherapy * no prior radiotherapy for other prior malignancy
application of the recommendations of the splif (french society of infectious pathology) in a geriatric population on the duration of treatment for bacterial pneumonia

Conditions: Pneumonia, Bacterial; Pneumopathy

Summary: pneumopathy is the leading cause of death from infectious disease in the elderly. prior to 2021, the recommended duration of antibiotic therapy for pneumonia, in adults, was 7 days. two theses have shown that these recommendations were poorly applied in geriatric services. indeed, the duration of treatment exceeded 7 days, and less than 30% of antibiotic antibiotic treatments were re-evaluated at 72 hours. in 2021, the splif ( published new recommendations reducing this duration to 5 days in the event of clinical improvement observed on the 3rd day of treatment. these new recommendations are based on studies, in which the average age of participants was 65 years. however, the average age of patients in geriatric short-stay departments is 84.7 years. in addition, the geriatric population is characterized by immunosenescence, pulmonary vulnerability and undernutrition, raising questions about the validity of these recommendations in the geriatric population. the investigators offer a monocentric, retrospective, observational study of the geriatric hospital casanova to assess the application of splif recommendations in the geriatric population.


Eligibility criteria:
inclusion criteria: * all patient treated for bacterial/community/nosocomial pneumonia who stayed in the geriatric short-stay at casanova's hospital between january 2, 2023 and april 30, 2023 exclusion criteria: * hiv positif * immunosupressed patient * complicated pneumonia (abcess, pleuropneumonia)

Keywords: pneumopathy bacterial nosocomial
long-term multicenter evaluation of the e1® tibial bearing

Conditions: Osteoarthritis of the Knee; Traumatic Arthritis of the Knee

Summary: this study has been designed to document the long-term outcome of the e1® tibial bearings used with the vanguard® knee system in 500 patients receiving total knee arthroplasty. all patients will receive the e1® tibial bearing in a vanguard® knee replacement. radiographic analysis and patient reported outcomes will be used as follow-up measures to track wear, mechanical performance, and patient satisfaction.


Eligibility criteria:
inclusion criteria: * male or female * 20 to 75 years of age * subjects requiring total knee replacement * subjects with the diagnosis of osteoarthritis, or traumatic arthritis * subjects who demonstrate the ability to return to massachusetts general hospital for follow-up for the next 10 years exclusion criteria: * subjects with osteoporosis, osteomalacia, or neuromuscular disease * incomplete or insufficient soft tissue around the knee * subjects with a limited life span * subjects who have difficulty comprehending the study protocol for any reason * subjects with disorders which may impair bone formation * subjects whose bony structure deviates substantially from the general norm * female subjects that are, or may become, pregnant while participating in this study

Keywords: clinical outcomes radiographic outcomes total knee arthroplasty survivorship
observational study on the use of akynzeo® in patients receiving hec

Conditions: Chemotherapy-Induced Nausea and Vomiting

Summary: this canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology patients receiving highly emetogenic chemotherapy (hec).

the study will assess quality of life using the functional living index of emesis (flie) questionnaire and generate real world evidence in support of existing clinical trial data, including effectiveness and safety of akynzeo® in the real world setting for the prevention of chemotherapy induced nausea and vomiting (cinv) in patients receiving highly emetogenic chemotherapy (hec).

Eligibility criteria:
inclusion criteria: subjects must satisfy the following criteria to be enrolled in the study: 1. patient scheduled to receive a highly emetogenic chemotherapy (hec). 2. patient scheduled to receive antiemetic prevention with akynzeo® according to the approved canadian product monograph as deemed medically necessary by the participating physician independently from this study. 3. age ≥ 18 years. 4. women of childbearing potential must use effective contraception during therapy and up to one month after treatment with akynzeo®. 5. patient (and/or patient's authorized legal representative) should understand the nature of the study and provide written informed consent prior to or at the screening visit. 6. patient is able and willing to comply with the study protocol for the entire length of the study and will follow all study requirements, procedures and complete all visits as required. 7. patient is participating in another clinical trial where antiemetic treatment is not pre-specified by the study protocol. exclusion criteria: 1. women of child bearing potential who are pregnant, planning on becoming pregnant or breast feeding. 2. hypersensitivity to active substances, excipients or other ingredients of akynzeo®. 3. concomitant use of pimozide, terfenadine, astemizole, or cisapride. 4. patient currently enrolled in another clinical trial where antiemetic treatment is pre-specified by the study protocol.
air pollution and health of copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this panel study aims to evaluate the effects of air pollutants on cardiopulmonary health of patients with chronic obstructive pulmonary disease (copd) and explore the potential biological mechanisms.

this panel study was conducted in a group of stable patients with copd in beijing, china. the health measurements including lung function, blood pressure and airway inflammation were conducted, and morning urine, exhaled breath condensate, saliva and venous blood were collected at the time of enrollment and at 3, 6 and 9 months after enrollment. individual exposures to fine particulate matter (pm2.5), black carbon (bc), ozone (o3) and nitrogen dioxide (no2) were performed for 24 hours at each follow-up. and the daily concentrations of air pollutants were collected from the beijing air quality real-time publishing platform and meteorological data were collected from the national meteorological information center. the linear mixed effects model was used to analyze the association between air pollution and cardiopulmonary health in patients with copd.

Eligibility criteria:
inclusion criteria: * doctor-diagnosed stable copd patients * aged 40 to 80 years * lived in beijing for over one year before being recruited * agree to participate and sign the informed consent form. exclusion criteria: * patients with a history of acute exacerbation in the last 1 month * patients with other respiratory diseases such as bronchiectasis and asthma.

Keywords: air pollution chronic obstructive pulmonary disease cardiopulmonary health biological mechanism
paclitaxel in treating women with recurrent solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of paclitaxel in treating women who have recurrent solid tumors.

objectives: i. evaluate the relationships between body surface area (bsa) and toxic effects, bsa and pharmacokinetics, and pharmacokinetics and toxic effects in women with recurrent solid tumors who receive a fixed total dose of paclitaxel. ii. determine the toxic effects of paclitaxel in these patients. iii. assess the pharmacokinetics of paclitaxel in these patients. outline: patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. patients are evaluated for response after the second course. patients are followed at the discretion of the physician. projected accrual: a total of 50 patients will be accrued over 13 months.

Eligibility criteria:
disease characteristics: histologically proven recurrent adult solid tumors must have measurable or evaluable disease no known bone marrow metastasis patient characteristics: age: 18 and over sex: women performance status: zubrod 0-2 life expectancy: not specified hematopoietic: absolute granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin less than 1.5 mg/dl sgot less than 2.0 times upper limit of normal renal: creatinine no greater than 1.5 times upper limit of normal other: concurrently active secondary malignancies are allowed prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior paclitaxel therapy no more than 1 prior chemotherapy regimen for metastatic disease at least 4 weeks since chemotherapy greater than 6 weeks since nitrosoureas, melphalan, or mitomycin endocrine therapy: not specified radiotherapy: at least 4 weeks since radiotherapy no prior whole pelvic radiation surgery: at least 4 weeks since major surgery

Keywords: unspecified adult solid tumor, protocol specific
familial partial lipodystrophy study

Conditions: Lipodystrophy, Familial Partial

Summary: studying patients with rare adipose tissue disorders may help the investigators to better understand the pathophysiology of diabetes and dyslipidemia in relation to adiposity, and thus have an enormous impact on public health.

a systematic study of body fat distribution is necessary to better define the phenotypic spectrum of fpl, and to better recognize fpl in patients with metabolic syndrome. similarly, genetic studies in these patients will not only help better characterize the genotype-phenotype relationship, but is also likely to help identify other genes involved in regulation of lipid homeostasis, as some patients may not have any of the known mutations. the investigators will systematically study mitochondrial protein quality and function under fasting and fed state in relation to intramyocellular and circulating plasma lipid levels, and compare with age, sex and bmi-matched individuals. the investigators will also study the rate of de-novo protein synthesis to determine if hyperinsulinemia affects both muscle protein anabolism and catabolism.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of lipodystrophy (decreased subcutaneous fat) 2. family history of lipodystrophy 3. normal control subject exclusion criteria: 1. inability to provide informed consent 2. hemoglobin \< 10g%

Keywords: fpl adipose tissue diabetes dyslipidemia metabolic hyperinsulinemia
the effect of dhea on markers of ovarian reserve in women with diminished ovarian reserve

Conditions: Infertility

Summary: this prospective study evaluates the effect of dhea supplementation on markers of ovarian reserve in women with diminished ovarian reserve.

ovarian reserve markers, such as fsh, estradiol, amh, ovarian volume and antral follicle counts will be monitored on dhea supplementation in a prospective fashion.

Eligibility criteria:
inclusion criteria: * infertile women with diminished ovarian reserve exclusion criteria: * women \> 45

Keywords: ovarian reserve fsh anti-mullerian hormone estradiol oocyte ivf embryo transfer
pufas in preterm infants

Conditions: Necrotizing Enterocolitis; Intraventricular Hemorrhage; BPD - Bronchopulmonary Dysplasia; Sepsis; Periventricular Leukomalacia; Patent Ductus Arteriosus

Summary: the research endeavors to examine the critical composition of polyunsaturated fatty acids (pufas) in premature infants across different gestational stages and under varying disease conditions, and delineate the metabolic attributes of pufas in premature infants and their interplay with the onset of diseases. this study anticipates furnishing a theoretical foundation for the rationalization of pufas supplementation in premature infants and for informing strategies related to disease prevention and management.


Eligibility criteria:
inclusion criteria: infants born between 24 and 36 weeks of gestational age who are admitted within 24 hours of birth, including both premature and full-term newborns. - exclusion criteria: infants with severe congenital developmental abnormalities, those requiring external supplementation of pufas in addition to standard intravenous nutrition and breastfeeding, and those with a severe prognosis indicating non-survival during their hospitalization. -

Keywords: pufas
the effects of azithromycin ophthalmic solution, 1% versus placebo in subjects with blepharitis during a four-week treatment period (p08638)

Conditions: Blepharitis

Summary: the objective of this study is to compare the safety and efficacy of azithromycin ophthalmic solution, 1% versus placebo over a four-week treatment period.


Eligibility criteria:
inclusion criteria: * have best corrected visual acuity in both eyes of at least +0.7 or better * if female, are non-pregnant or non-lactating * have a current diagnosis of blepharitis in one or both eyes exclusion criteria: * have lid structural abnormalities * have suspected ocular fungal or viral infection * have practiced warm compress therapy within 14 days prior to visit 2 * unable to withhold the use of contact lenses during the treatment or follow-up periods * unable to withhold the use of ocular cosmetic products within 24 hours prior to study visits * have had penetrating intraocular surgery within 90 days prior to visit 2 * have had ocular surface surgery within the past year prior to visit 2 * have a serious medical condition which could confound study assessments
minimal invasiveness of endoscopic thyroidectomy

Conditions: Thyroid Nodule

Summary: the investigators had performed more than 250 cases of breast approach endoscopic thyroidectomy (baet). the goal of this study is to evaluate whether baet could be a minimally invasive procedure under the expert's hands.


Eligibility criteria:
inclusion criteria: * thyroidectomy nodule diagnosed by ultrasound exclusion criteria: * thyroid carcinoma
safety, tolerability, and activity of isis 113715 in people with type 2 diabetes mellitus who have not received prior treatment

Conditions: Type 2 Diabetes Mellitus

Summary: the aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five isis 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus of less than 5 years in duration * have never received hypoglycemic therapy * aged 18 to 65 years * fasting blood glucose between 130 and 220 mg/dl (7.2 to 12.2 mmol/l) for cohorts a-d and between 140 and 220 mg/dl (7.8 to 12.2 mmol/l) for cohort e * hba1c between 6.8 and 10.0% for cohorts a-d and between 7.5 and 11.0% for cohort e * body mass index \> 25 and \< 35 kg m -2 exclusion criteria: * medication that may affect glucose homeostasis (e.g. systemic glucocorticoid) within one month of screening * clinically significant abnormalities in medical history or physical exam * clinically significant abnormalities on laboratory examination * history of hiv infection * active infection requiring antiviral or antimicrobial therapy * malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \> one year at the time of screening) * any other concurrent condition which, in the opinion of the investigator, would preclude participation in or interfere with compliance * alcohol or drug abuse * undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days of screening * abnormal serum creatinine concentration defined as \> 1.5 mg/dl (132.6 micro mol/l) for males and \> 1.2 mg/dl (106 micro mol/l) for females * medications that may affect coagulation (heparin, warfarin, etc.) with the exception of acetylsalicylic acid or non-steroidal anti-inflammatory agents. * allergy to sulfur-containing medications

Keywords: fasting plasma glucose hba1c